- Display 15 Products per page
Published: January 1, 2007 | Price: $995.00 – $7,000.00
The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years. Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and...Published: May 1, 2007 | Price: $995.00 – $3,990.00
Cancer is the second most common cause of death in the industrialized world. At this time, treatment for cancer focuses on some combination of surgery, radiation, and chemotherapy. But over the next five years, treatment is going to dramatically change. as detailed in the report Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market from Kalorama Information. One of the most promising new approaches in modern cancer treatment is immunotherapy, the development of methods to augment and enhance the...Published: June 1, 2007 | Price: $995.00 – $1,990.00
The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. As illustrated by Kenneth G. Krul, Phd., in Kalorama Information's Global Tuberculosis Strategies, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. As the author details, there are primarily three focal...Published: July 1, 2007 | Price: $995.00 – $3,990.00
In light of laboratory pressures to do more with less, laboratory managers transfer cost control onto vendors by means of a constant push for price reductions. In this commercial climate, efficient management of customer and technical service extras is critical. Expertise in managing service offerings will help companies offer service programs that are just enough to differentiate them from the competition. Service programs that offer too much may result in revenue loss. Programs that are perceived to be inadequate place...Published: August 1, 2007 | Price: $995.00 – $1,990.00
The unrecognized importance, danger and costs of hepatitis in the 21st century cannot be understated or underestimated. The impact of the disease on world society is highly significant and now presenting a major crisis in public health circles. In his exhaustive analysis of the potential diagnosis, screening and therapeutic markets for hepatitis, Ken Krul, PhD. advises companies to think on a global basis. In this study, Global Hepatitis Strategies Krul examines the potential market, epidemiology (hepatitis patient trends) and technology...Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...Published: October 1, 2007 | Price: $995.00 – $1,990.00
For food ingredient companies willing to enter the non-food market, there is over a billion dollars of market potential awaiting them. In addition to increasing the profitability of their traditional product lines, producers of ingredients can potentially expand their markets by moving their products or byproducts into the healthcare sector, where drug producers or manufacturers of some biomedical devices could incorporate them into their products. Kalorama Information's Healthcare Opportunities for Food Ingredient Manufacturers details the sources of ancillary revenue that...Published: October 1, 2007 | Price: $995.00 – $5,990.00
Retail clinics, also known as convenience clinics, represent a disruptive innovation into the U.S. health care market, which evolved from and is uniquely positioned to benefit from the health care system’s shortcomings. These clinics present a new opportunity for retail outlets to earn more revenue from rents and 'indirect' revenues from sales to the retail store as a result of a clinic visit. But there is also an opportunity for diagnostic and pharmaceutical companies to capitalize on this trend. Kalorama...Published: October 1, 2007 | Price: $995.00 – $5,000.00
In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...Published: November 1, 2007 | Price: $995.00 – $5,495.00
Analytical microchips can be considered one of the fastest growing technology segments in life sciences. The range of applications to which these miniature laboratories may be directed is very broad — covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis. Kalorama's Analytical Chip Technology: U.S. Markets for Lab on a Chip, DNA/Gene, Protein and other Microarrasys) 3rd. Edition looks at the market for analytical microchips with a unique methodology -- the market is expressed...Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...Published: January 1, 2008 | Price: $995.00 – $1,990.00
Improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts. Rejection remains the major barrier to long-term graft survival in patients, organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ. Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used....Published: January 1, 2008 | Price: $995.00 – $7,990.00
Parts of the gene expression analysis market continue to develop in a somewhat predictable manner, whereas other segments are becoming increasingly complex and volatile. The main products—microarrays and RT-PCR—continue to gain widespread acceptance and to see revenues grow rapidly. However, different products and applications are increasingly being introduced, making the market more fragmented as well as unpredictable. In terms of application, too, the landscape is shifting. Although life-science research is still the dominant application, the clinical diagnostics and prognostics market...